Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shenkang
- Development stage
- Phase 4
- Lead developer
- Xi'an Century Shengkang Pharmaceutical
- Administration
- Intravenous, Rectal, Oral
01
Overview
Shenkang is a traditional Chinese medicine (TCM) used for the treatment of chronic kidney disease (CKD), available in various formulations including injection (SKI), granules (SKG), and suppositories (SKS). The formula consists of several herbs, primarily rhubarb (Rheum palmatum L.), safflower (Carthamus tinctorius L.), astragalus (Astragalus mongholicus Bunge), and red sage (Salvia miltiorrhiza Bunge). [1, 3] Its therapeutic effects in CKD are attributed to its ability to reduce renal fibrosis, inflammation, and oxidative stress. [5, 6] Mechanistically, Shenkang has been shown to inhibit the renin-angiotensin system (RAS) by blocking the Wnt/β-catenin signaling pathway. [11] It also modulates other pathways, including PI3K/Akt and MAPK. [1, 5] Active components responsible for its effects include anthraquinones like rhein and emodin, as well as hydroxysafflor yellow A, tanshinol, and astragaloside IV. [5]
- Brand names
- Shenkang
- Other names
- Shenkang InjectionShenkang GranulesShenkang suppository肾康栓
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)JAK2 (Janus kinase 2)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)PIK3CA (Phosphoinositide 3-kinase alpha)STAT3 (Signal Transducer and Activator of Transcription 3)SMAD7 (Mothers against decapentaplegic homolog 7)TGFBR1AGTR1 (Angiotensin II Type-1 receptor)ACE (Angiotensin Converting Enzyme)CTNNB1 (Beta-catenin)NF-κBPI3K (Phosphoinositide-3-kinase regulatory subunit 6)AKT (RAC-alpha serine/threonine-protein kinase)WNT1 (Wnt family member 1)
Beyond the preview
Go deeper on shenkang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shenkang.